UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 23, 2016
Interpace Diagnostics Group, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-24249 |
|
22-2919486 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
Morris Corporate Center 1, Building A
300 Interpace Parkway
Parsippany, NJ 07054
(Address, including zip code, of Principal Executive Offices)
(855) 776-6419
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Item 3.01. |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On November 23, 2016, Interpace Diagnostics Group, Inc. (the “Company”) received written notice from the Listing Qualifications department (the “Staff”) of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2016 reported total stockholders’ (deficit) equity of ($1,479,000). In its written notice to the Company, the Staff also notified the Company that, as of November 22, 2016, it did not meet the alternative requirements based on the market value of listed securities or net income from continuing operations.
In its written notice to the Company, the Staff notified the Company that it has 45 calendar days to submit a plan to regain compliance and that, if the Company’s plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the notification letter, November 23, 2016, to regain compliance. The Staff further notified the Company that if its plan to regain compliance is not accepted, the Company will have the opportunity to appeal that decision to a Hearings Panel.
The Company is currently considering available options regarding its compliance with Nasdaq Listing Rule 5550(b)(1).
signatureS
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Interpace Diagnostics Group, Inc. | ||
|
Date: November 29, 2016 |
By: |
/s/ Jack E. Stover |
| Name: | Jack E. Stover | |
| Title: | President and Chief Executive Officer | |